Jakafi, which was discovered by Incyte (ticker: INCY) and is sold outside of the U.S. by Novartis (NVsureS) as Jakavi, is approved by the Food and Drug Administration to treat a number of cancers.“The potential that Jakavi could lead to faster recovery times for COVID-19 patients with fewer requiring intensive care and mechanical ventilation is encouraging and absolutely merits further investigation,” said Novartis’s head of global drug development and chief medical officer, John Tsai.